Biotechnology

Bionoid Pharma, Inc. Unveils Five-Year Strategic Roadmap

November 5, 2024 7:25 AM

Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) has outlined a five-year roadmap focused on expanding revenue streams and brand presence through a targeted acquisition strategy and a shift toward long-term profitability. Within the first 24 months, BINP plans to acquire revenue-generating websites in the health and wellness sector, with the ultimate goal of achieving a 15% EBITDA margin by year five. Central to this vision is the development and...

Read more

Interim Report July-September 2024

November 5, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / November 05, 2024 /Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for third quarter 2024. "This past quarter was a pivotal period for Vicore, as we continue to make significant strides towards our long-term vision of improving treatment outcomes for patients suffering from...

Read more

Tharimmune Announces Upcoming Conference Presentations

November 4, 2024 9:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences. Randy Milby, Chief Executive Officer, will attend the 2024 Spartan Capital Investor Conference being held on November 4, 2024 in New York and hold one-on-one meetings. Interested investors...

Read more

Nitches Inc Launches Groundbreaking Veteran-Led Testing for InTheZone Focused Extreme, With Promising Early Results

November 4, 2024 8:00 AM

Nitches Inc (OTC PINK:NICH) is proud to announce that we have begun our highly anticipated Phase One testing, led by a distinguished U.S. Army veteran, who served as a First Sergeant in Aviation and operated in high-stress roles. This testing is focused on gathering real-world feedback from veterans, law enforcement, and firefighters who operate in intense, high-stakes environments. Due to his notable rank and service, we're withholding his...

Read more

Vicore announces the Nomination Committee for the 2025 Annual General Meeting

November 4, 2024 3:20 AM

STOCKHOLM, SE / ACCESSWIRE / November 04, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, November 4, 2024 - Vicore Pharma Holding AB (publ) (STO:VICO) ("Vicore"), a clinical-stage pharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has appointed the Nomination Committee for the 2025 Annual General Meeting. The three largest shareholders as of August 31, 2024,...

Read more

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

October 31, 2024 4:05 PM

President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence...

Read more

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

October 31, 2024 8:35 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today reported financial results for the third quarter 2024. "We are working diligently to collect and analyze the definitive data that we need to complete our PMA application seeking approval from the FDA for the VenoValve and we look forward to releasing that data to the public," commented Robert...

Read more

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies

October 31, 2024 6:00 AM

AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the expansion of a previous agreement with Gilead Sciences, Inc. (Nasdaq:GILD) to develop novel antibody discovery technologies and discover therapeutic antibodies for Gilead-selected targets. Under the initial agreement in June 2023, AbTherx received worldwide rights to Atlas™ Mice, a suite of...

Read more

Increase in Number of Shares and Votes in Vicore Pharma

October 31, 2024 4:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / October 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, October 31, 2024 - Vicore Pharma Holding AB (publ) (STO: VICO) ("Vicore"), a clinical-stage pharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the number of Vicore shares and votes has increased following (i) the rights issue of shares resolved by the...

Read more

Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB

October 31, 2024 3:40 AM

LUND, SE / ACCESSWIRE / October 31, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden, October 31, 2024 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on May 7, 2025, has been appointed. Pursuant to the instruction for the Nomination Committee adopted by the AGM in 2019, the Nomination Committee for the Alligator Bioscience AGM 2025 shall...

Read more

BioInvent International AB: Interim Report January-September 2024

October 31, 2024 3:20 AM

LUND, SWEDEN / ACCESSWIRE / October 31, 2024 / BioInvent International (STO:BINV) "Progress to date brings the company one step closer to addressing the needs for new treatment solutions for patients. As part of our Q3 report, we are today pleased to present continued positive data from the Phase 1 part of the study with BI-1206 as a subcutaneous (SC) formulation for the treatment of NHL. We now have another complete response (CR) and another...

Read more

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

October 30, 2024 8:00 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a Scientific Advice meeting with the European Medicines Agency (EMA) that included guidance on a planned Phase 2 trial to advance TH104, the Company's lead clinical-stage candidate for moderate-to-severe pruritus in primary biliary...

Read more

The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) Selects Indica Labs' HALO AP to Deliver AI-enabled Diagnostics

October 30, 2024 8:00 AM

The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), among the leading institutes for clinical digital pathology and research in the European Union, has partnered with Indica Labs to implement digital primary diagnostics with integrated AI-powered image analysis. IPATIMUP selected the HALO AP® enterprise digital pathology platform from Indica Labs for seamless integration of both off-the-shelf and...

Read more

Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024

October 30, 2024 3:50 AM

LUND, SE / ACCESSWIRE / October 30, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 2024: Investors and Partnering Conferences ØU Life Science Investor Conference , October 30, Copenhagen Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments and upcoming...

Read more

Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening

October 30, 2024 3:00 AM

LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases, is pleased to announce the schedule for the opening of the first clinical site for its lead asset, HEMO-CAR-T, formally designated HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. The Company has successfully completed the necessary...

Read more

Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

October 29, 2024 11:15 AM

LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / October 29, 2024 / Alligator Bioscience AB ("Alligator") (STO:ATORX)(ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced that new, positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Friday, November 8, 2024, at the Society for Immunotherapy of Cancer 2024 (SITC), taking place November 6th -...

Read more

Invitation to Presentation of BioInvent’s Interim Report January - September 2024

October 29, 2024 5:35 AM

LUND, SE / ACCESSWIRE / October 29, 2024 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2024 at 5:00 pm CET on Thursday October 31. The report will be published at 8:00 am CET the same day. BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The...

Read more

Tanvex CDMO to Exhibit at the 15th Annual World ADC Conference in San Diego

October 28, 2024 2:15 PM

SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Tanvex CDMO announced its participation as an exhibitor in the 15th Annual World ADC Conference, taking place from November 4-7, 2024, at the Town & Country San Diego. Attendees are invited to visit Booth #416 to connect with the Tanvex CDMO team of experts, explore collaboration opportunities, and share insights on the latest trends in bispecific process development and formulation, cell-based...

Read more

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

October 28, 2024 9:00 AM

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profile TH104 was well tolerated with no unexpected treatment-emergent adverse events, supporting further clinical development Company expects Phase 2 topline data for chronic pruritus in primary biliary cholangitis (PBC) patients in 2025 BRIDGEWATER, NJ / ACCESSWIRE / October 28, 2024 /...

Read more

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

October 28, 2024 8:30 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful start to its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The first wave of implants, for the long-term subjects, was successfully completed, with the final wave for the shorter-term subjects scheduled for December....

Read more